Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1350-1357

  Eisen, T ^a   Smith, I E ^a   Jonnston, S ^a   Ellis, P A ^a   Prendiville, J ^a   Seymour, M T ^a   Walsh, G ^a   Ashley, S ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; ERYTHEMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0031949961     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1350     Document Type: Article

References (27)

1. Cameron DA, Gabra H, Leonard RCF, et al: Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70:120-124, 1994
2. Hansen R, Quebbeman E, Beatty P, et al: Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 10:145-149, 1987
3. Hatfield AK, Johnson PA, Egner JR, et al: Long term continuous 5-fluorouracil infusion in the treatment for far advanced breast cancer. Proc Am Soc Clin Oncol 8:35, 1989 (abstr)
4. Huan S, Padzur R, Singhakowinda A, et al: Low dose continuous 5-fluorouracil. Evaluation in advanced breast cancer. Cancer 63:149-422, 1989
5. Jones AL, Smith IE, O'Brien MER, et al: Phase II study of continuous infusion fluorouracil in epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: An active new regimen. J Clin Oncol 12:1259-1265, 1994
6. Smith IE, Walsh G, Jones A, et al: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13:424-429, 1995
7. Findlay M, Norman A, Mansi J, et al: A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous infusional 5-FU (ECF). Br J Cancer 67:4.3, 1993 (suppl 20)
8. Calvert AH, Newell DR, Gumbrell LA, et al: Early clinical studies with cis-diainmine-1 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140-147, 1982
9. Henderson K, Harris JR, Kinne DW, et al: Cancer of the breast, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1989, pp 1197-1268
10. Bennett JM, Muss HB, Doroshow DH, et al: A randomized, multicenter, trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast cancer. J Clin Oncol 6:1611-1620, 1988
11. Simon R, Wittes RE, Ellenberg SS: Randomised phase II clinical trials. Cancer Treat Rrep 69:1375-1381, 1985
12. Haagensen CD, Stout AP: Carcinoma of the breast: Criteria of inoperability. Ann Surg 118:859-870, 1943
13. Beahrs O, Henson D, Rulter R, et al (eds): Manual for Staging of Cancer (ed 3). Philadelphia, PA, Lippincott, 1988, pp 145-150
14. Bern MM, Lokich JJ, Wallach SR, et al: Very low dose of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112:423-428, 1990
15. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
16. Hayward JL, Carbone PP, Heuson J-C, et al: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89-94, 1977
17. Millar AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
18. Kaplan E, Meier P: Non-parametric observation from incomplete observations. J Am Stat Assoc 53:457-482, 1958
19. Jones AL, Walsh G, Smith IE: Primary medical (neoadjuvant) chemotherapy with infusional 5-FU, epirubicin and cisplatin for large operable breast cancer: A very active new regimen. Br J Cancer 67:406-410, 1991
20. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523-1533, 1987
21. Jodrell DI, Smith IE, Mansi JL, et al: A randomised comparative trial of mitoxantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5-FU (CMF) in the treatment of advanced breast cancer. Br J Cancer 63:794-798, 1991
22. Powells TJ, Jones AL, Judson IR, et al: A randomised trial comparing combination chemotherapy using mitomycin C, mitoxantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer 64:406-410, 191
23. Eddy DM: High dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncl 10:657-670, 1992
24. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment of metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
25. Bonnefois H, Smith IE, O'Brien MER, et al: Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): A very active and well-tolerated outpatient regimen. Br J Cancer 73:391-396, 1996
26. Fisher B, Wicherham DL: Preoperative systemic therapy for the treatment of primary breast cancer, in Powles TJ, Smith IE (eds): Medical Management of Breast Cancer. London, United Kingdom, Dunitz, 1991, pp 281-286
27. Smith IE, Jones AL, O'Brien MER, et al: Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer 29A: 1796-1799, 1993